We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Stay up to date on the topics that matter to you

Featured Articles

Antibodies

Biologic Production and Host Cell Proteins

Host cell proteins can prove problematic for the development of novel biopharmaceuticals. This article will highlight some of the latest advances in host cell analysis strategies and how they are being implemented.

A scientist loading samples into a microwell plate.

Advances in CHO Cell Line Development for Biotherapeutics

A diverse array of biological medicines are now used to prevent and treat a wide range of illnesses. This article will discuss the development of cell lines in biopharma and will touch on key considerations, such as future manufacturability.

Droplets of liquid falling from pipette tips into a multiwell plate.

Extracting Meaningful Data With High-Throughput Drug Discovery Approaches

This article focuses on the use of high-throughput screening approaches in drug discovery and discusses the latest developments in this area.

Latest Articles

Agendas online

The conference agendas for ADMET Europe, MedChem Europe, Pharma Outsourcing Congress and Flow Chemistry Europe to be held 28-29 March, 2011 in Munich, Germany have now been released.

Agendas online

The conference agendas for Advances in qPCR, RNAi & miRNA World Congress, Epigenetics World Congress and Next-Gen Sequencing Congress to be held 26-27 April, 2011 in Boston, MA, USA have now been released.

Fast growth MAb market to offer great rewards to a select few over 2009-15

Datamonitor predicts that the MAb sector will record a near double-digit growth rate over 2009-15, making it the fastest growing molecule type segment in the prescription pharmaceutical industry. With total sales derived by a select band of blockbuster products, the MAb sector is a tough market to break in to, but one that offers high rewards.

Cytheris Initiates INSPIRE 3, a Phase II Clinical Trial of CYT107 in Chronically Infected HIV Patients

Phase II clinical program will evaluate the effect of repeated cycles of the company’s investigative immune-modulator in the treatment of Immunological Non-Responders.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter